Concepedia

Author

Iain J. Mulford

Novartis Institutes for BioMedical Research

Also Known As

Iain J. Mulford, Iain Mulford, Mulford, I.J.

20

Publications

461

Citations

6

H-Index

27

Concepts

All Affiliations

Novartis Institutes for BioMedical ResearchNovartis (Switzerland)
IJ

About

Iain J. Mulford is an author at Novartis Institutes for BioMedical Research specializing in medicine, cell biology, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

307

2

Cell Biology

4

4

307

3

Engineering

1

1

14

4

Health Sciences

1

1

28

5

Cellular Physiology

1

1

58

Iain J. Mulford

×

6

Publications

454

Citations

6

H-Index

YearCitations

Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer

Sana Raoof, Iain J. Mulford, Heidie Frisco Cabanos,

Oncogene

2019

207

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

Sunkyu Kim, Ralph Tiedt, Alice Loo,

Oncotarget

2018

88

Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

Hui Qin Wang, Iain J. Mulford, Fiona A. Sharp,

Cancer Research

2021

59

Inducible expression of TGFβ, Snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model

Gretchen Argast, Joseph S. Krueger, Stuart Thomson,

Clinical & Experimental Metastasis

2011

58

Cooperative Signaling between Oncostatin M, Hepatocyte Growth Factor and Transforming Growth Factor-β Enhances Epithelial to Mesenchymal Transition in Lung and Pancreatic Tumor Models

Gretchen Argast, Peter Mercado, Iain J. Mulford,

Cells Tissues Organs

2010

28

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors

Ralph Tiedt, Frederick J. King, Christelle Stamm,

Cell Reports

2023

14

Page 1